Qsymia Results: What to Realistically Expect

What the Trials Actually Showed

Three randomized controlled trials form the evidence base for Qsymia's weight-loss efficacy:

A few things to understand about these numbers:

• They are means (averages across hundreds of patients). Individual loss ranged from zero to over 25%.
• They are placebo-subtracted (the reported number is the drug arm's loss minus the placebo arm's loss). The placebo arm in Qsymia trials received lifestyle intervention alone and still lost 1–2%.
• They are intent-to-treat, meaning discontinuations were included in the denominator — not just the patients who completed the full trial.
• Real-world adherence is lower than trial adherence. Expect to see somewhat smaller losses in unselected clinical populations than in the trial numbers.

When Does Qsymia Start Working?

The sequence of effects is reasonably predictable:

• Day 1–3: Topiramate-related taste changes begin (carbonated drinks taste flat, some foods taste metallic). This is usually the first sign the drug is active.
• Day 3–7: Appetite suppression becomes noticeable. Patients often describe feeling less hungry between meals, smaller portions satisfying, or outright lack of interest in food at certain times of day.
• Week 1–2: Early paresthesia may begin (tingling in hands, feet). Dry mouth and mild insomnia can show up at this point.
• Week 2–3: Weight change becomes measurable on the scale, beyond normal daily fluctuation.
• Week 3 (dose escalation to 7.5/46): Weight loss accelerates.
• Week 12: The FDA checkpoint. Most responders are clearly losing by this point; non-responders are identifiable.

1-Month Qsymia Results

The first month on Qsymia is mostly the starter dose (3.75/23) plus the first week of the recommended dose (7.5/46). Weight loss in this period is modest because the starter dose is low, intentionally, to build tolerance to the side-effect profile.

Ranges reflect the interquartile to 90th-percentile spread seen in pivotal trial data for month-1 loss on the standard titration. Higher starting weights tend to see larger absolute losses early.

3-Month Qsymia Results

By month 3, patients have typically been on the recommended 7.5/46 dose for 10 weeks. This is the FDA-designated checkpoint at which the clinician decides to continue, titrate up, or discontinue.

• Mean weight loss: 5–7% of baseline body weight (10–14 lb for a 200-lb patient)
• Responders (≥3% loss — continue on 7.5/46): ~70% of patients
• Partial responders (<3% loss — titrate to 15/92): ~20% of patients
• Non-responders (minimal loss — discontinue): ~10% of patients

Note: this is the single most important decision point in Qsymia therapy. If the 12-week number is not there, continuing at the same dose rarely produces meaningful additional loss.

1-Year Qsymia Results

At 56 weeks in pivotal trials, the pooled data looks like this:

A 200-pound patient at the trial-mean 15/92 outcome would be 180 pounds at 1 year. A high-responder (top quartile) at 15/92 would be 165–170 pounds. A low-responder might be essentially unchanged. The drug helps the average patient; it is not guaranteed to help any specific patient.

2-Year Results (SEQUEL)

SEQUEL was the 52-week extension of CONQUER, following a subset of patients through a total of 108 weeks (~2 years). The key findings:

• Weight loss was largely maintained. The 1-year mean of 9.8% on 15/92 was largely preserved through 2 years (ending at ~10.5%). Most of the loss happened in year 1.
• Additional year-2 loss was small. On average, patients who completed year 2 lost an additional 1–2% beyond year 1 — not nothing, but not linear continued loss either.
• Side-effect profile was stable. Side effects that were going to discontinue a patient usually did so in year 1; patients who reached year 2 on therapy tolerated year 2 similarly.
• Cardiometabolic benefits held. Blood pressure, HbA1c, and lipids improved in year 1 and those improvements were maintained in year 2 for patients who maintained weight loss.

SEQUEL is also the longest Qsymia trial on record — published real-world data beyond 2 years is thin. For many patients, year 2 is the practical end of useful Qsymia therapy regardless of how well it worked in year 1, either because of plateau or because of accumulated side-effect burden.

Responders vs Non-Responders

The most reliable predictor of whether Qsymia will work long-term is early response. Patients who lose at least 3% of their weight in the first 4 weeks typically go on to lose clinically meaningful weight at 6 and 12 months. Patients who lose less than 3% in month 1 often never catch up.

Factors that favor strong response, based on subgroup analyses of CONQUER/EQUIP:

• Higher starting BMI (more room to lose, and metabolic adaptation is steeper)
• Female sex (slight favor in response rates — reasons incompletely understood)
• Type 2 diabetes (appetite changes appear stronger in this subgroup)
• Binge-eating-pattern eating behaviors (topiramate specifically helps)
• Good tolerance of the starter dose (high tolerance often predicts ability to reach 15/92)

Factors associated with non-response:

• Minimal change in eating patterns despite starting the drug
• Very low starting BMI (near the 27 threshold — smaller absolute loss expected)
• Concurrent medications that increase appetite (antipsychotics, certain antidepressants)
• Binge-episode patterns that don't respond to topiramate

Qsymia Reviews — Patterns From Aggregated Patient Experience

Aggregating public patient reviews (Drugs.com, WebMD, Reddit weight-loss communities) produces a few consistent patterns. We don't cherry-pick — the patterns below reflect the tone of the overall distribution, not selected high or low reviews.

What positive Qsymia reviewers tend to say

• Appetite suppression kicked in within the first week
• "I don't think about food all the time anymore"
• Sugar and carbonated-drink cravings noticeably reduced
• Steady weight loss through the first 6 months
• Cheaper than Wegovy, doesn't require injections
• Doctor was supportive, REMS paperwork was manageable

What negative Qsymia reviewers tend to say

• Brain fog and word-finding difficulty that didn't resolve
• Insomnia that persisted even with morning-only dosing
• Tingling (paresthesia) that continued for months
• Hair thinning / shedding (attributed either to topiramate or rapid weight loss)
• Frustration with REMS-pharmacy process and shipping delays
• Expected results that didn't materialize — "I barely lost anything"
• Abrupt discontinuation required due to pregnancy, glaucoma, or mood changes

Aggregate rating across the major patient-review sites sits in the 6.8–7.2 / 10 range. For comparison, Wegovy and Zepbound user reviews sit in the 7.8–8.4 / 10 range on the same sites. Both classes have patients who love them and patients who hate them; the distribution just tilts further toward "love" on GLP-1s.

Before and After Photos — The Reality

"Qsymia before and after" is one of the most-searched related terms, and there's a reason we don't reproduce photos on this page: verification is impossible for individual photos circulating online, and a curated selection of dramatic results would misrepresent typical outcomes.

What you would actually see, if you took a statistically representative sample of patients at 1 year:

• About 3 in 10: visible change, mostly in midsection and face (clothes fit differently, photographs show change)
• About 4 in 10: modest change (5–10% body weight) — visible to close family but not dramatic in photographs
• About 3 in 10: minimal to no visible change — lost 0–3%, often discontinued

For a patient looking at a dramatic before-and-after photo on social media, the reasonable prior is that this is a top-decile responder — not a typical one. Set expectations against the trial means, not against the curated outcomes.

Maintaining Results After Stopping Qsymia

Like every weight-loss medication, Qsymia is effective while it's being taken and less effective after it stops. Patients who stopped Qsymia at the end of the CONQUER/SEQUEL trials regained roughly 2–4% within 6 months and somewhat more over 12 months — still below pre-treatment weight, but drift upward is the norm.

Factors that improve maintenance:

• Sustained lifestyle changes built during the active-drug period
• Continued monitoring at 3- to 6-month intervals
• Transition to a maintenance medication if appropriate (lower-dose Qsymia, GLP-1 at maintenance dose)
• Ongoing behavioral support / accountability

Stopping abruptly and returning to pre-drug eating patterns is the most reliable path to regaining weight.

Same Timeline, Different Numbers (GLP-1)

Side-by-side expected weight loss at each timepoint:

The gap widens over time. At month 1, the two classes are comparable. By 1 year, GLP-1s produce 1.5× more weight loss on average. By 2 years, the gap is stable because most Qsymia loss happens in year 1.